-
公开(公告)号：EP4223786A2
公开(公告)日：2023-08-09
申请号：EP23165932.7
申请日：2016-03-07
申请人： Public University Corporation Yokohama City University , Public University Corporation Nagoya City University , Pharma Foods International Co., Ltd.
发明人： Sato, Mamoru , Yamada, Michiyuki , Kanazawa, Satoshi , Toyoura, Masayoshi , Shoya, Yuji , Saito, Kenji , Yamazaki, Chihiro
摘要： Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0 × 10 -9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.
-
公开(公告)号：EP4223786A3
公开(公告)日：2023-08-16
申请号：EP23165932.7
申请日：2016-03-07
申请人： Public University Corporation Yokohama City University , Public University Corporation Nagoya City University , Pharma Foods International Co., Ltd.
发明人： Sato, Mamoru , Yamada, Michiyuki , Kanazawa, Satoshi , Toyoura, Masayoshi , Shoya, Yuji , Saito, Kenji , Yamazaki, Chihiro
摘要： Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0 × 10 -9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.
-
搜索结果
2 条记录 (耗时 0.019 秒)
